Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Diabetes-Cancer Link Could Inform Future Screening Efforts

      July 22, 2016
      By Brielle Urciuoli
      Article

      A greater likelihood of developing most types of cancer was found to be associated with type 2 diabetes, according to findings of a large Canadian study published recently online in the journal Cancer.

      Iliana Lega, MD

      Iliana Lega, MD

      Iliana Lega, MD

      A greater likelihood of developing most types of cancer was found to be associated with type 2 diabetes, according to findings of a large Canadian study published recently online in the journal Cancer. The strongest correlation was 10 years prior to, and 3 months after, a diabetes diagnosis, and the findings could, with further study, help to inform enhanced cancer screening programs targeted for those at higher risk.

      Individuals with diabetes were more likely to have been diagnosed with a first cancer within the decade before diabetes diagnosis, when compared with those without diabetes. Once diagnosed with diabetes, an increase in cancer was observed during the first 3 months, as those with diabetes had a 62% greater chance of being diagnosed with cancer than those without diabetes.

      “This may, in part, be explained by increased healthcare visits and screening tests following a diagnosis of diabetes,” said study author Iliana Lega, MD, a clinical scientist at the University of Toronto, in a statement. After the 3-month mark, the difference in cancer statistics between those with diabetes and those without leveled off.

      While detection bias may play a role in the number of cancer diagnoses within the first few months of a diabetes diagnosis, the reason for the higher prevalence (23%) of cancer a decade prior likely has more to do with the risk factors leading up to diabetes, independent of seeing a doctor.

      “This observation may be due to shared metabolic risk factors for diabetes and cancer that are present during the prediabetes period, such as insulin resistance and hyperinsulinemia,” the study’s authors wrote. “These metabolic alterations may precede a clinical diagnosis of diabetes by up to 10 years.”

      The study looked at 516,219 patients with diabetes, and matched them with a control group of 516,219 individuals without diabetes. All patients were aged ≥30 years, leading the study to reflect cancer risk for type 2 diabetes, since type 1 diabetes is rare in this age group, Lega said in an interview with Oncology Nursing News.

      Diabetes was associated with a “significantly increased risk” of pancreatic, endometrial, liver, and thyroid cancers in both time periods studied. There was a jump in colorectal and bladder cancers within the first 3 months of a diabetes diagnosis, but it then leveled off.

      As diabetes rates continue to grow in many countries, including the United States, study emphasized the importance of intervention and prevention.

      “We have excellent evidence that diabetes can be reversed with physical activity and lifestyle interventions in high-risk individuals,” they wrote. “Such interventions are urgently needed both on an individual and population level, not only to reduce the risk of diabetes and vascular complications, but also to potentially reduce the burden of cancer in this population.”

      Further, Lega mentioned that increased screening could improve outcomes for people with diabetes who may potentially have cancer as well.

      “Our findings suggest that people with diabetes, and even those at risk for diabetes, may have a higher risk of cancer and therefore may benefit from enhanced cancer screening and prevention programs,” she said. “However, more research is needed to assess how to best implement such targeted programs in this high-risk population.”

      Lega IC, Wilton AS, Austin PC, et al. The temporal relationship between diabetes and cancer: a population-based study [published online ahead of print July 11, 2016]. Cancer.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Image of a woman wearing a patterned shirt in front of a dark blue background
      Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
      3 experts in this video
      3 experts in this video
      Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
      Related Content

      Line illustration of a lung on a cornflower blue background

      Neoadjuvant Nivolumab Regimen Improves OS in Resectable NSCLC

      Kristi Rosa
      June 15th 2025
      Article

      Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.


      The Vitals

      What New Cancer Drugs Were Approved in 2023?

      Lindsay Fischer
      January 1st 2024
      Podcast

      In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.


      Image of a person holding a model of the female reproductive system

      Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

      Gina Mauro
      June 13th 2025
      Article

      Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.


      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.


      Graphic that resembles a stamp of approval reading "FDA Approved"

      FDA Approves Perioperative Pembrolizumab in Head and Neck SCC

      Bridget Hoyt
      June 12th 2025
      Article

      The FDA approved a perioperative pembrolizumab regimen in head and neck squamous cell carcinoma, marking the first approval in this cancer type in 6 years.


      Graphic of a clipboard that reads "FDA"

      Zanubrutinib Tablets Greenlit by FDA for All Approved Indications

      Bridget Hoyt
      June 12th 2025
      Article

      An oral tablet formulation of zanubrutinib was approved for use in patients with certain lymphomas or leukemia and Waldenström macroglobulinemia.

      Related Content

      Line illustration of a lung on a cornflower blue background

      Neoadjuvant Nivolumab Regimen Improves OS in Resectable NSCLC

      Kristi Rosa
      June 15th 2025
      Article

      Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.


      The Vitals

      What New Cancer Drugs Were Approved in 2023?

      Lindsay Fischer
      January 1st 2024
      Podcast

      In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.


      Image of a person holding a model of the female reproductive system

      Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

      Gina Mauro
      June 13th 2025
      Article

      Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.


      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.


      Graphic that resembles a stamp of approval reading "FDA Approved"

      FDA Approves Perioperative Pembrolizumab in Head and Neck SCC

      Bridget Hoyt
      June 12th 2025
      Article

      The FDA approved a perioperative pembrolizumab regimen in head and neck squamous cell carcinoma, marking the first approval in this cancer type in 6 years.


      Graphic of a clipboard that reads "FDA"

      Zanubrutinib Tablets Greenlit by FDA for All Approved Indications

      Bridget Hoyt
      June 12th 2025
      Article

      An oral tablet formulation of zanubrutinib was approved for use in patients with certain lymphomas or leukemia and Waldenström macroglobulinemia.

      Latest Conference Coverage

      Neoadjuvant Nivolumab Regimen Improves OS in Resectable NSCLC

      Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.